Literature DB >> 19154662

Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria.

Guillermo J Ruiz-Delgado1, Eduardo Vázquez-Garza, Nereida Méndez-Ramírez, David Gómez-Almaguer.   

Abstract

The regulatory proteins CD55 and CD59 are glycolsylphosphatidylinositol-anchored, type I cell surface proteins, which inhibit formation of the C3 convertases and prevent the terminal polymerization of the membrane attack complexes, respectively. Paroxysmal nocturnal hemoglobinuria (PNH) is a genetic disorder due to the impaired conformation of the glycolsylphosphatidylinositol anchor, which results in the deficient expression of CD55 and CD59 leading to excessive destruction of red cells and leukocytes. We have studied the expression of these two molecules in red blood cells, granulocytes and platelets in patients with PNH (two patients), autoimmune hemolytic anemia (AIHA) (seven patients), autoimmune thrombocytopenia (ATP) (22 patients), systemic lupus erythematosus (SLE) (19 patients), aplastic anemia (AA) (eight patients), and Evans syndrome (ES) (two patients). A diminished expression of CD55 and CD59 was found in the three cell lines of the two patients with PNH. In the seven patients with AIHA two were found with CD59 diminished expression in red blood cells and one with CD59 diminished expression in granulocytes. In the patients with ATP one was found with CD55 diminished expression in red blood cells, one with CD59 diminished expression granulocytes and one with a CD59 diminished expression in the platelets. In the subset of patients with SLE only one was found with a CD55 diminished expression in the red blood cells. In the patients with AA, a diminished expression in red blood cells was not found; however, one patient was found with a diminished expression of CD59 in granulocytes, and one patient with a diminished expression of CD55 in the platelets. In the two patients with ES we did not found changes in the expression of CD55 and CD59. We conclude that the diminished expression of the glycolsylphosphatidylinositol-anchored type I cell surface proteins CD55 and CD59 is not specific to PNH and that it can be found in patients with a variety of autoimmune disorders. Additional studies are needed to define the role of the deficiencies of CD55 and CD59 in the pathogenesis of autoimmune hemocytopenias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19154662     DOI: 10.1179/102453309X385089

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  11 in total

1.  Altered Expression Pattern of CD55 and CD59 on Red Blood Cells in Anemia of Chronic Kidney Disease.

Authors:  Lama Al-Faris; Salah Al-Humood; Fatma Behbehani; Husam Sallam
Journal:  Med Princ Pract       Date:  2017-09-28       Impact factor: 1.927

Review 2.  Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature.

Authors:  Erik Anderson; Bhakti Shah; Anne Davidson; Richard Furie
Journal:  Semin Arthritis Rheum       Date:  2017-12-08       Impact factor: 5.532

3.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

4.  Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Authors:  Ellinor I B Peerschke; Biree Andemariam; Wei Yin; James B Bussel
Journal:  Br J Haematol       Date:  2009-11-19       Impact factor: 6.998

5.  Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report.

Authors:  Norio Nakamura; Toshiyuki Sugawara; Ken-Ichi Shirato; Ryuichiro Kumasaka; Masayuki Nakamura; Michiko Shimada; Takeshi Fujita; Reiichi Murakami; Yuko Shimaya; Hiroshi Osawa; Hideaki Yamabe; Ken Okumura
Journal:  J Med Case Rep       Date:  2011-11-14

6.  The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon.

Authors:  John V Asimakopoulos; Evangelos Terpos; Loula Papageorgiou; Olga Kampouropoulou; Dimitris Christoulas; Anastasios Giakoumis; Michael Samarkos; George Vaiopoulos; Konstantinos Konstantopoulos; Maria K Angelopoulou; Theodoros P Vassilakopoulos; John Meletis
Journal:  Med Sci Monit       Date:  2014-01-27

7.  A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Abdülkerim Yıldız; Merih Kızıl Çakar; Elif Suyanı; Gülsan Türköz Sucak
Journal:  Turk J Haematol       Date:  2014-09-05       Impact factor: 1.831

8.  The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major.

Authors:  Ayşegül Uğur Kurtoğllu; Belkıs Koçtekin; Erdal Kurtoğlu; Mustafa Yildiz
Journal:  Arch Med Sci       Date:  2018-12-30       Impact factor: 3.318

Review 9.  "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.

Authors:  Astha Malik; Unmesha Thanekar; Surya Amarachintha; Reena Mourya; Shreya Nalluri; Alexander Bondoc; Pranavkumar Shivakumar
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 5.738

Review 10.  Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry.

Authors:  Margarida Lima
Journal:  Pract Lab Med       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.